ETR028/ETR029
/ Elysium Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 13, 2023
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: Elysium Therapeutics, Inc. | Trial completion date: Mar 2023 ➔ Mar 2024 | Trial primary completion date: Mar 2023 ➔ Mar 2024
Trial completion date • Trial primary completion date • Pain
October 07, 2022
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: Elysium Therapeutics, Inc.
New P1 trial • Pain
1 to 2
Of
2
Go to page
1